Prognostic value of KRAS mutations in patients with advanced primary liver cancer treated with transcatheter arterial chemoembolization
10.3969/j.issn.1001-5256.2022.11.015
- VernacularTitle:KRAS基因突变对经肝动脉化疗栓塞术治疗的中晚期原发性肝癌患者预后的预测价值
- Author:
Xuchu LIU
1
;
Shiyun QIN
1
;
Lijun CHEN
1
;
Juan CHEN
2
;
Xiaoguang YOU
3
Author Information
1. Tumor Treatment Center, Sanya Central Hospital, The Third People's Hospital of Hainan Province, Sanya, Hainan 572000, China
2. Department of Pharmacy, Sanya Central Hospital, The Third People's Hospital of Hainan Province, Sanya, Hainan 572000, China
3. Department of Radiology, the First Affiliated Hospital of Hainan Medical College, Haikou 570102, China
- Publication Type:Original Articles_Liver Neoplasms
- Keywords:
Liver Neoplasms;
Genes;
Chemoembolization, Therapeutic;
Prognosis
- From:
Journal of Clinical Hepatology
2022;38(11):2514-2519
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the prognostic value of KRAS mutation in patients with advanced primary liver cancer treated with transcatheter arterial chemoembolization (TACE). Methods Ninety-seven patients with advanced primary liver cancer who received TACE treatment in The Third People's hospital from April 2017 to May 2020 were included. The mutation status of KRAS was detected, and its relationship with the prognosis of TACE was investigated. The t -test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. Survival analysis was performed using Kaplan-Meier survival curve and compared using Log-rank test. Cox regression analysis was performed to identify the prognostic factors. Results Among 97 patients with advanced liver cancer, KRAS mutations were detected in 34 patients (35.05%), including 21 patients with codon 12 mutation (61.76%) and 13 patients with codon 13 mutation (38.24%). KRAS mutation was associated with liver cirrhosis, intrahepatic metastasis and the number of tumors ( χ 2 =0.035, 3.965, and 6.593, all P < 0.05). Survival analysis showed that the progression free survival and overall survival were significantly longer in KRAS wild-type patients than in KRAS mutant patients ( χ 2 =4.465 and 4.280, all P < 0.05). Multivariate Cox analysis revealed that KRAS mutation, intrahepatic metastasis, number of tumors and BCLC stage were important factors affecting the overall survival and prognosis of patients (all P < 0.05). Conclusion KRAS mutation is common in patients with advanced primary liver cancer and is closely associated with a poor prognosis after TACE. It may become a potential indicator of clinical prognosis.
